What type of study is this?

This is a Systematic Review study.

What question did this study set out to answer?

To evaluate the effectiveness and safety of mepolizumab for treating hypereosinophilic syndrome (HES).

November 14, 2025Frontiers in ImmunologyOpen Access

Mepolizumab for hypereosinophilic syndrome: effectiveness and safety from real-world evidence

View Full Paper

Ask AI

Bookmark

Authors

EMElvira Mora MFMaria Laura Fox MFMaria Laura Fox

Discussion

Member takes

Implication

Observational evidence shows mepolizumab reduces eosinophil levels in hypereosinophilic syndrome patients, indicating safety and glucocorticoid sparing.

Key Points

To evaluate the effectiveness and safety of mepolizumab for treating hypereosinophilic syndrome (HES).
Conducted a scoping review following PRISMA Scoping Reviews Checklist
Identified 36 relevant references for mepolizumab use in HES
Reviewed treatment dosages (100–750 mg), administration routes, and schedules (every 2–12 weeks).
Remission rates ranged from 57.1% to 76.0%
Mean blood eosinophil counts reduced by 71.4% to 99.1% with mepolizumab treatment
85.7% of patients discontinued glucocorticoids after 12 months
Mepolizumab was well-tolerated with rare severe adverse events.

Cite This Study

Mora et al. (2025) studied this question.

synapsesocial.com/papers/692519acc0ce034ddc35416b https://doi.org/10.3389/fimmu.2025.1704077

View Full Paper

Ask AI

Bookmark

Implication

Observational evidence shows mepolizumab reduces eosinophil levels in hypereosinophilic syndrome patients, indicating safety and glucocorticoid sparing.